Contact Us
Finding a rock-solid connection can be tough, because it’s difficult to show whether the infections are the cause of autoimmune disorders or whether they crop…
READ MORE
Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the…
READ MORE
Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be used to support the company’s…
READ MORE
With its pipeline of bacteria-fighting monoclonal antibodies, Aridis is working to tackle the first two problems: injecting innovation into the space and testing its programs…
READ MORE
Office interactions are definitely an important way to foster relationships between coworkers, establish and maintain a corporate culture, and foster creative thinking. This is particularly…
READ MORE
“The biggest thing that is really happening in the biotech industry…there is a new rich source of drugs. There is a goldmine, called mRNA, that…
READ MORE
Immuneering Corp., a Cambridge, Mass.-based startup that uses computational technology for drug discovery, completed a $62 million Series B round. Cormorant Asset Management led the…
READ MORE
Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag,…
Listen here
The review received financial support from Avadel Pharmaceuticals, which recently filed a new drug application with the US Food & Drug Administration (FDA) for a…
READ MORE
Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own…
READ MORE
Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseasesincluding Parkinson’s disease.
READ MORE
With crossover investors lining up to participate, biotechs Immuneering and Terns each raised…
READ MORE
Before any biologic drug enters into the clinic, it is essential to have a clear understanding of what exactly the biomolecule entails, according to Vu…
READ MORE
OncoSec’s vaccine, CORVax12, being developed in partnership with Providence Cancer Center in Portland, uses a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed in the National…
READ MORE
August was also Healthy Aging Month and, to get some perspective on the topic, we spoke to Stanford’s Dr Thomas Rando, best known for his…
READ MORE
Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently…
View clip
Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral…
Listen here
Peptidream Inc. inked a research collaboration with Amolyt Pharma SAS to test and optimize Peptidream’s growth hormone receptor antagonist (GHRA) peptides, with the aim of…
READ MORE
X4 Pharma is a company focused on delivering innovative treatments for patients with rare diseases of the immune system. With the COVID pandemic afflicting patients…
READ MORE
Penny stock biotech Seneca Biopharma has found a lifeline in privately owned Leading BioSciences as it merges with the biotech.
READ MORE
We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for…
View clip
Buffalo-formed biopharmaceutical company Athenex just got FDA approval for a topical ointment to treat it, called Klisyri.
READ MORE
A little over a month after a full company rebrand, the Biotech Formerly Known as Axovant has its first data readout under its new moniker.
READ MORE
Scientists at Recce design these antibiotics to attach to proteins in the plasma membrane of pathogens via hydrophobic interactions, which trigger cell lysis. “The bacteria…
READ MORE
At a macro level across the globe, there is an increasing cadence, on an exponential curve, in the ability to translate basic insights into therapeutics.…
READ MORE
GigaGen Inc.’s co-founder and Chief Executive Officer, explained that for decades scientists working with emerging pathogens had been concerned about the possibility of a pandemic,…
READ MORE
One such company is Vaxart, based in South San Francisco, which is currently in Phase 1 human trials for a COVID-19 vaccine that’s taken as…
READ MORE
Next year could be pivotal for Aridis. It anticipates inflection points for three immunotherapy programs and is making available for licensing its rapid mAb development…
READ MORE
Rocket Pharmaceuticals (RCKT) announced positive Phase 1 test results for a gene therapy in heart disease — prompting RCKT stock to surge Wednesday.
READ MORE
Abpro Corp., a biotechnology company developing next generation antibody therapies for severe disease, is targeting a more robust antibody response with its therapeutic, ABP 300,…
READ MORE
While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…
READ MORE
About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual…
READ MORE
Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.
READ MORE
Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a…
READ MORE
“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A…
READ MORE
Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide…
READ MORE
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics…
READ MORE
“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We…
READ MORE
Vaxart, a San Francisco-based biotechnology company, is testing a tablet-form Covid-19 vaccine to tackle storage temperature problems, which affect even rich countries like the US,…
READ MORE
Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on…
READ MORE
The drug in question, Cerevance, significantly improved cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trail, details the…
READ MORE
Cue Biopharma has managed to persevere through the COVID pandemic by employing a variety of strategies. President and Chief Scientific Officer, Anish Suri, and Ken…
READ MORE
Chiasma was trading 4% higher in the opening minutes on Wednesday.
READ MORE
Cambridge Science Park-based Cerevance has confirmed positive results from a trial of a potential treatment for cognitive impairment associated with schizophrenia.
READ MORE
Christopher J. Barnum, PhD, of INmune Bio, Inc discusses XPro1595, developed by INmune Bio, and how it may provide neuroprotective benefits for those at risk…
READ MORE
OSE Immunotherapeutics is among the companies pursuing this signaling pathway, and it has unveiled preclinical data supporting a novel strategy for disrupting it.
READ MORE
Any time we have an opportunity to talk with Jeff Wolf, we take it – especially when the conversation tackles the highs and lows of…
READ MORE
Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a…
READ MORE
As marketability goes—and despite a growing unmet medical need—Lyme disease vaccine programs have suffered a futile fate. With its VLA15 candidate, French specialty vaccine company…
READ MORE
Nantkwest Executive Chairman Dr. Patrick Soon-Shiong weighs in on Pfizer data and discusses the coronavirus vaccine trial process.
View clip
Aiming to shed the legacy of an epic Alzheimer’s fail a few years ago, Axovant $AXGT is changing its name in a full corporate rebrand.…
READ MORE
Heat Biologics in Research Triangle Park is also working on a vaccine to combine with one like Pfizer’s to generate a more robust immune response.
READ MORE
Jewish Hospital has treated its first patient as part of a national study that hopes to prevent the progression of pulmonary complications due to COVID-19.
READ MORE
Though a COVID-19 vaccine could be released by year’s end or soon after, healthcare professionals say getting it to everyone who needs it is expected…
READ MORE
Two genetic signatures that Rain Therapeutics scientists are focusing on are MDM2 gene amplification and wild-type p53 status, which tend to be exclusive events in…
READ MORE
China’s Clover Biopharma is getting another boost as it gears up for a global, pivotal trial of its COVID-19 vaccine. The Coalition for Epidemic Preparedness…
READ MORE
South San Francisco-based Vaxart recently announced they had entered into a phase 1 trial for their VXA-CoV2-1 vaccine. Vaxart is a biotechnology company developing a range…
READ MORE
Paula Ragan, Ph.D., is one of those leaders and one of a select group who not only was mentored by Termeer — an industry legend…
READ MORE
Compugen Ltd. recently presented new research data further supporting the PVRIG protein coding gene as a potentially promising target for cancer immunotherapy. These data suggest that…
READ MORE
Several analogues of parathyroid hormone in different formulations are being developed to provide more long-lasting effects of the molecule. AZP-3601 (Amolyt Pharma) is one of…
READ MORE
Aridis Pharmaceuticals founder, CEO, and Director Vu Truong, Ph. D. doesn’t think the 8,000 milligram dose of Regeneron’s SARS-CoV-2 Virus Multi-Antibody Therapy (REGN-COV2) given to…
READ MORE
On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard…
READ MORE
9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare…
READ MORE
Immuneering uses bioinformatics to develop new medicines while also helping large pharmaceutical companies improve their treatments.
READ MORE
A Woburn-based biotech company says it’s seeing early success with COVID-19 antibody treatments. Scientists at Abpro have been studying antibodies for a decade but the…
View clip
We at NeuBase have felt that there are fundamental deficiencies in the current approach to drug development. The traditional drug screening approach, which involves scouring…
READ MORE
Immunitybio Chairman and CEO Dr. Patrick Soon-Shiong joins ‘Maria Bartiromo’s Wall Street’ to discuss
View clip
A couple months after raising CHF 2.5 million ($2.76 million) in initial seed funding, one-year-old Araris Biotech is topping off the round with another CHF…
READ MORE
Rezolute, a small company based in Redwood City, California, and working in the rare pediatric disease space, is developing a new therapeutic option specifically for…
READ MORE
Amolyt Pharma, formerly Alizé Pharma 3, had announced earlier this year its plans to start a clinical trial of AZP-3601 by the end of 2020.
READ MORE
Aridis Pharmaceuticals is working on an inhaled neutralizing antibody for COVID-19 dubbed AR-711, which was discovered using samples from patients who had recovered from COVID-19.…
READ MORE
Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr.…
READ MORE
Moira speaks with Dr. Levi Garraway, the Chief Medical Officer of Genentech about FDA approvals for treatments in two very rare diseases – SMA –…
Listen here
Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second…
READ MORE
Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. talks KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three…
Listen here
Cidara Therapeutics has adopted key immuno-oncology principles and applied them to infectious disease, enabling the creation of a novel antiviral strategy – antiviral conjugates (AVCs). AVCs…
READ MORE
An oral coronavirus vaccine candidate has entered the clinical trial phase, bringing with it a possible option for those wary of needles. Vaxart Inc. announced on Tuesday that the…
READ MORE